# Consistency between Primary Uterine Corpus Malignancies and Their Corresponding Patient-Derived Xenograft Models

## TL;DR

This study shows that patient-derived xenograft models of uterine tumors closely mirror the original tumors in terms of appearance, genetic makeup, and RNA profiles, making them useful for personalized medicine.

## Contribution

The study demonstrates high consistency between primary uterine tumors and their xenograft models in histology, gene mutations, and extracellular RNA profiles.

## Key findings

- 52 out of 92 patient-derived xenograft models were successfully established with a 56.5% success rate.
- Primary and xenograft tumors showed similar histological, immunohistochemical, and genetic features.
- RNA profiles of extracellular vesicles from primary and xenograft tumors were comparable.

## Abstract

Patient-derived xenograft (PDX) models retain the characteristics of tumors and are useful tools for personalized therapy and translational research. In this study, we aimed to establish PDX models for uterine corpus malignancies (UC-PDX) and analyze their similarities. Tissue fragments obtained from 92 patients with uterine corpus malignancies were transplanted subcutaneously into immunodeficient mice. Histological and immunohistochemical analyses were performed to compare tumors of patients with PDX tumors. DNA and RNA sequencing were performed to validate the genetic profile. Furthermore, the RNA in extracellular vesicles (EVs) extracted from primary and PDX tumors was analyzed. Among the 92 cases, 52 UC-PDX models were established, with a success rate of 56.5%. The success rate depended on tumor histology and staging. The pathological and immunohistochemical features of primary and PDX tumors were similar. DNA sequencing revealed similarities in gene mutations between the primary and PDX tumors. RNA sequencing showed similarities in gene expressions between primary and PDX tumors. Furthermore, the RNA profiles of the EVs obtained from primary and PDX tumors were similar. As UC-PDX retained the pathological and immunohistochemical features and gene profiles of primary tumors, they may provide a platform for developing personalized medicine and translational research.